13
Jul

Otsuka and its partner Lundbeck snagged an FDA approval for Rexulti (brexpiprazole) to treat schizophrenia and as an add-on therapy for major depression, leaving the two companies prepping for an August launch into an increasingly crowded field.

…read more

Source: As schizophrenia rivals rush in, Otsuka and Lundbeck gain FDA OK for Rexulti

    

0 No comments